Payment overview · 2025
General Payments
$1,418.99
72 reported records · 13 companies
Healthcare provider profile · identity verified
Eman Ayed Abusalah, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DEARBORN HEIGHTS, MI · NPI 1043915812
Verified facts
What the public records show
CMS Open Payments records show Eman Ayed Abusalah, FNP-C received $1,418.99 in general payments during 2025 across 72 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Mounjaro, Nurtec Odt, Ozempic, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $401.97 | 28.3% | 18 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $201.43 | 14.2% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $168.76 | 11.9% | 6 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.96 | 11.2% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $137.46 | 9.7% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $97.55 | 6.9% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $89.79 | 6.3% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.77 | 2.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.85 | 2.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.82 | 2.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.37 | 1.5% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $19.88 | 1.4% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $14.38 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,418.99 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $201.43 | 13 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $158.96 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $147.91 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $117.08 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $94.90 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $89.79 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $62.14 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $58.66 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.89 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.82 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.82 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.18 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 66 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 187 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
187 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 485 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 450 | 106 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 449 | 91 |
| Diclofenac Sodium | Diclofenac Sodium | 380 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 89 |
| Fluticasone Propionate | Fluticasone Propionate | 335 | 73 |
| Omeprazole | Omeprazole | 327 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 56 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 241 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 238 | 53 |
| Lisinopril | Lisinopril | 232 | 52 |
| Ibuprofen | Ibuprofen | 216 | 41 |
| Losartan Potassium | Losartan Potassium | 214 | 41 |
| Gabapentin | Gabapentin | 212 | 52 |
| Simvastatin | Simvastatin | 209 | 37 |
| Metformin Hcl | Metformin Hcl | 207 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 192 | 48 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 187 | 42 |
| Furosemide | Furosemide | 182 | 47 |
| Trazodone Hcl | Trazodone Hcl | 180 | 40 |
| Alprazolam | Alprazolam | 170 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 152 | 27 |
| Meloxicam | Meloxicam | 149 | 37 |
| Prednisone | Prednisone | 130 | 67 |
| Famotidine | Famotidine | 129 | 23 |
| Ondansetron Odt | Ondansetron | 129 | 28 |
| Montelukast Sodium | Montelukast Sodium | 128 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 125 | 28 |
| Pregabalin | Pregabalin | 119 | 18 |
| Potassium Chloride | Potassium Chloride | 115 | 28 |
| Ventolin Hfa | Albuterol Sulfate | 114 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 26 |
| Sertraline Hcl | Sertraline Hcl | 108 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 104 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 22 |
| Nystatin | Nystatin | 94 | 20 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 93 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 90 | 15 |
| Baclofen | Baclofen | 79 | 24 |
| Meclizine Hcl | Meclizine Hcl | 79 | 15 |
| Glipizide Er | Glipizide | 76 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 73 | 11 |
| Diazepam | Diazepam | 71 | 17 |
| Carvedilol | Carvedilol | 70 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 13 |
| Trulicity | Dulaglutide | 69 | 19 |
| Buspirone Hcl | Buspirone Hcl | 66 | 12 |
| Eliquis | Apixaban | 66 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 15 |
| Ketoconazole | Ketoconazole | 66 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 21 |
| Glipizide | Glipizide | 62 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 14 |
| Ammonium Lactate | Ammonium Lactate | 60 | 14 |
| Clonidine Hcl | Clonidine Hcl | 60 | 16 |
| Ozempic | Semaglutide | 60 | 14 |
| Lidocaine | Lidocaine | 59 | 13 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 57 | 23 |
| Metformin Hcl Er | Metformin Hcl | 55 | 13 |
| Mirtazapine | Mirtazapine | 55 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 54 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | suppressed |
| Azithromycin | Azithromycin | 52 | 41 |
| Bumetanide | Bumetanide | 52 | 12 |
| Fluconazole | Fluconazole | 52 | 25 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 51 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | 14 |
| Klor-Con 10 | Potassium Chloride | 50 | suppressed |
| Spironolactone | Spironolactone | 47 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 28 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 43 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 12 |
| Hydrocortisone | Hydrocortisone | 41 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 13 |
| Loperamide | Loperamide Hcl | 41 | 17 |
| Mupirocin | Mupirocin | 41 | 19 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 32 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Calcitriol | Calcitriol | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Naproxen | Naproxen | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | 11 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 34 | suppressed |
| Acyclovir | Acyclovir | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 22 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Comfort Touch Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Nystop | Nystatin | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 15 |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 19 | 15 |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 11 |
| Novolog | Insulin Aspart | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Desloratadine | Desloratadine | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 13 | suppressed |
| Tretinoin | Tretinoin | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Comfort Ez Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,418.99 · 72 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, GVOKE HYPOPEN, LINZESS, MOUNJARO, NURTEC ODT, Natroba, Ozempic, PREVNAR 20, REXULTI, Rybelsus, Spinosad, TMS NeuroHealth Centers Inc., TRELEGY ELLIPTA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error